Introduction
============

HER-2 is one of four Erb B family-type I receptor tyrosine kinases and is the preferred dimerisation partner for the epidermal growth factor receptor \[[@B1],[@B2]\]. The Erb B receptors are important in normal development and in human cancer. HER-2, independent of its own ligand, activates other Erb B receptors to increase their ligand affinity and to amplify biological responses. HER-2 plays a key role in activating cytoplasmic signalling through the phosphatidylinositol-3 kinase (PI-3K)/protein kinase *B*(Akt) and mitogen-activated protein kinase pathways to influence transcription of nuclear genes \[[@B2]-[@B4]\]. Activation of PI-3K/Akt is involved in cell proliferation and confers resistance to apoptosis \[[@B5],[@B6]\]. Breast cancer is associated with deregulated expression of HER-2, detectable as HER-2 amplification or protein overexpression identified in 10--40% of tumours \[[@B7]\]. HER-2 expression is indicative of poor prognosis and may predict tumour responses to hormone therapy and chemotherapy.

Cell cycle progression is regulated by cyclin-dependent kinases (CDKs) associated with cyclin proteins. p21^*WAF*1/*CIP*1^, a downstream target of p53, is a CDK inhibitor that re-enforces p53-mediated G1 and G2 arrest following genotoxic insults, to facilitate DNA repair \[[@B8]-[@B11]\]. The integrity of G1 and G2 checkpoints requires the nuclear localisation of p21^*WAF*1/*CIP*1^\[[@B11],[@B12]\]. Recent evidence including subcellular fractionation suggests that p21^*WAF*1/*CIP*1^can localise in the cytoplasm in cancer tissues and cell lines, where it inhibits apoptosis by binding and inhibiting the apoptosis signal-regulating kinase 1 \[[@B13]-[@B17]\]. Such an anti-apoptotic function in breast cancers could underlie the association between cytoplasmic p21^*WAF*1/*CIP*1^and poor prognosis \[[@B17]\]. Upregulation of p21^*WAF*1/*CIP*1^occurs through PI-3K/Akt signalling, and may involve insulin-like growth factors, p53-dependent pathways or HER-2 expression \[[@B18]-[@B20]\]. A HER-2-overexpressing breast cancer cell line transcriptionally upregulates p21^*WAF*1/*CIP*1^and has been shown to produce its cytoplasmic localisation through a mechanism whereby Akt binds and phosphorylates p21^*WAF*1/*CIP*1^in its nuclear localisation signal \[[@B21]\]. *In vivo*HER-2 expression may involve changes in the subcellular localisation of p21^*WAF*1/*CIP*1^to influence the outcome in breast cancer.

We previously found that breast cancers with higher levels of cytoplasmic p21^*WAF*1/*CIP*1^predicted reduced overall survival (OS) and relapse-free survival (RFS), with correlation between cytoplasmic p21^*WAF*1/*CIP*1^and p53 expression on immunohistochemistry \[[@B17]\]. Recent *in vitro*findings demonstrated a direct influence of HER-2 on cytoplasmic p21^*WAF*1/*CIP*1^. This influence prompted us to investigate HER-2 expression in a retrospective series of breast cancers with p21^*WAF*1/*CIP*1^staining by immunohistochemistry and a further 4 years of patient follow-up \[[@B21]\]. We are not aware of any other study to date examining subcellular p21^*WAF*1/*CIP*1^expression in relation to HER-2 immunoreactivity.

Patients and methods
====================

Patients
--------

The study included 73 patients aged 32--80 years (median, 55 years) with primary infiltrating carcinoma diagnosed between 1989 and 1992 at the John Radcliffe Hospital. The eligibility criteria were histological diagnosis of breast carcinoma, level one or complete axillary lymph node dissection, no distant metastases and unilateral tumour. Forty-nine (67%) cases were node-negative and 24 (33%) cases were node-positive (N1-mobile ipsilateral or N2-fixed ipsilateral).

Clinicopathological subgroups were analysed according to the Nottingham Prognostic Index (NPI). They were divided into good, moderate and poor prognostic groups as previously described, with a modification that included no assessment of the internal mammary lymph nodes \[[@B22],[@B23]\]. Seventeen nongraded nonductal cancers were not included in the NPI groups.

Adjuvant treatment groups comprised tamoxifen (16 node-negative patients, 14 node-positive patients), cyclophosphamide/methotrexate/5-fluorouracil (six node-negative patients, six node-positive patients), and both tamoxifen plus cyclophosphamide/methotrexate/5-fluorouracil (two node-negative patients, four node-positive patients). Twenty-five node-negative women received no adjuvant treatment.

The median duration of follow-up was 110 months (range, 46--144 months) among patients who were alive at the date of their last visit. Tumour samples were collected shortly after surgery and were fixed in buffered formalin for 24--48 hours at room temperature. Tumours were classified according to Azzopardi \[[@B24]\]. Invasive ductal carcinomas were graded by the modified Bloom\'s grading system described by Elston and Ellis \[[@B25]\]. The oestrogen receptor (ER) status was determined using an ELISA assay (Abbott-ERICA; Abbott Laboratories, Maidenhead, UK). Tumours were classified as ER-positive if oestradiol binding exceeded 10 fmol/mg cytosolic protein.

Immunohistochemistry
--------------------

HER-2 immunostaining was performed using the mouse monoclonal anti-HER-2 antibody (RTU-CB11) (NovaCastra/ Vector, Newcastle upon Tyne, UK), and the DAKO Envision Plus HRP system (K4006; DAKO, Ely, Cambridgeshire, UK). Formalin-fixed paraffin sections of breast cancer tissue were baked, dewaxed and rehydrated prior to a peroxidase block (0.1%, v/v hydrogen peroxide) and an incubation in 10% v/v normal goat serum. The primary antibody and horseradish peroxide-labelled polymer were used as per the DAKO Envision kit, followed by 3,3-diaminobenzidine and counterstaining with haematoxylin before mounting.

HER-2 expression was scored according to the degree and the proportion of membrane staining \[[@B26]\]. HER-2 expression was negative for a score of 0 or 1+. A score of 0 was defined as no staining or membrane staining in less than 10% of tumour cells. A score of 1+ comprised faint or partly-stained membranes in more than 10% of tumour tissue. Overexpression of c-erbB2 was scored as 2+, defined as weak to moderate complete membrane staining in more than 10% of tumour cells. A score of 3+ was interpreted as strong, complete membrane staining in more than 10% of tumour. This was analysed in the Department of Clinical Laboratory Sciences (by RDL).

p21^*WAF*1/*CIP*1^immunoreactivity was evaluated using the mouse monoclonal antibody Ab-1 (Calbiochem, Cambridge, MA, USA) at 0.5 μg/ml. Biotinylated goat anti-mouse IgG (DAKO, Glostrup, Denmark) secondary antibody was used at 15 μg/ml. The Strept ABC Duet kit (DAKO, Denmark) was used for p21^*WAF*1/*CIP*^detection \[[@B17]\]. Immunostaining was assessed using a Laborlux microscope (Leitz, Wetzlar, Germany) at 400× overall magnification with a field diameter of 0.46 mm. p21^*WAF*1/*CIP*1^immunoreactivity was assessed as the degree of staining intensity and the proportion of cells with p21^*WAF*1/*CIP*1^in the nucleus and in the cytoplasm, which was graded semiquantitatively to produce an intensity distribution score (IDS) for each localisation \[[@B17]\]. Calculation of the IDS was performed as follows: IDS (maximum score 300) = 1 × per cent of weakly stained cells + 2 × per cent of moderately stained cells + 3 × per cent of strongly stained cells. Average IDS values were determined by examination of 10 fields \[[@B17]\].

Statistical analysis
--------------------

The association between HER-2 and patient characteristics was assessed using the Mann--Witney test for continuous variables and the chi-squared test for categorical factors. The relationship between HER-2 and the subcellular localisation of p21^*WAF*1/*CIP*1^was analysed using the Mann--Witney U test, with the p21^*WAF*1/*CIP*1^IDS used as a continuous variable. Analyses of survival data were performed using the log-rank test and the Cox regression model, with survival curves computed using the Kaplain--Meier method.

For both HER-2 and p21^*WAF*1/*CIP*1^markers univariate and multivariate analyses were performed, the latter adjusting for the NPI score and the treatment received (tamoxifen/ chemotherapy/no treatment). As the NPI is based on nodal involvement, on tumour size and on grade, patients with histologies for whom grade is undefined (\'other\' cancers) were excluded from the regression analyses. Thirteen patients (all either ductal carcinoma, lobular carcinoma or mixed histology) had no grade information recorded in the data and one patient had no tumour size recorded. These patients were included in the analysis using multiple imputation methods \[[@B27]\] to estimate the missing values.

The hazard ratios were derived from the average effect across 10 augmented datasets, with the confidence intervals and significance tests taking into account the uncertainty of the imputations. The multiple imputation was performed by the MICE library within the S-Plus 2000 Guide to Statistics Volumes 1 and 2 (MathSoft, Seattle, WA, USA), and all other analyses were performed using the STATA version 7 software (STATA Corporation, College Station, TX, USA) \[[@B28]\].

Results
=======

HER-2 expression and association with clinicopathologic factors
---------------------------------------------------------------

HER-2 immunoreactivity was evaluable in 67 (92%) cases, and scored positively in 13 (19%) cases (Fig. [1](#F1){ref-type="fig"}) using scoring of 2+ and 3+ as indicative of HER-2 protein overexpression. Tumours with HER-2 scores of 0 or 1+ were assessed as negative. HER-2 expression was analysed in relation to clinicopathologic criteria (Table [1](#T1){ref-type="table"}), with a significant association of HER-2 positivity with young age (≤ 50 years) (*P*= 0.03) and with ER-negative (≤ 10 fmol/mg) tumours (*P*= 0.05).

Association of HER-2 with subcellular localisation of p21^*WAF1/CIP1*^
----------------------------------------------------------------------

p21^*WAF*1/*CIP*1^expression measured as an IDS was analysed in the nucleus and in the cytoplasm in relation to HER-2 expression (Fig. [1](#F1){ref-type="fig"}). Nuclear p21^*WAFI*/*CIP*1^was higher in HER-2-negative tumours with a median IDS of 7.3 (range, 0--88.5), compared with a median IDS of 2.3 (range, 0--37.5) in HER-2-positive breast cancers (*P*= 0.05) (Fig. [2](#F2){ref-type="fig"}). Cytoplasmic p21^*WAF*1/*CIP*1^staining was significantly higher in HER-2-positive cancers with a median IDS of 95 (range, 12.5--154.5; *P*= 0.005), compared with HER-2-negative tumours with a median IDS of 47 (range, 0--134.6) (Fig. [2](#F2){ref-type="fig"}).

These results suggest that HER-2-positive tumours showed an increase in cytoplasmic p21^*WAF*1/*CIP*1^of 50 IDS units, compared with a decrease of 5 IDS units for nuclear p21^*WAF*1/*CIP*1^. Despite proportionately lower nuclear p21^*WAF*1/*CIP*1^levels on IDS, the HER-2-associated increase is far greater in terms of cytoplasmic immunoreactivity. This suggests that the association between cytoplasmic p21^*WAF*1/*CIP*1^and HER-2 positivity is stronger than for nuclear p21^*WAF*1/*CIP*1^.

Relationship of clinicopathological factors to prognosis and the predictive potential of HER-2 and p21^*WAF1/CIP1*^expression
-----------------------------------------------------------------------------------------------------------------------------

At 9 years, disease relapses were seen in 33 patients (22 of 48 node-negative patients and 11 of 25 node-positive patients); 30 women died from breast carcinoma. The 9-year RFS and OS were 52% and 61%, respectively. Poor prognostic factors such as the presence of lymph node metastases, high tumour grade, large tumour size and negative ER status were all associated with a lower percentage of patients remaining disease-free (RFS) and alive (OS) at 9 years (data not shown). The 5-year OS of the NPI subgroups were 67% (95% confidence interval, 19--95%) for the good prognostic group, 78% (95% confidence interval, 61--88%) for the moderate prognostic group and 40% (95% confidence interval, 12--67%) for the poor prognostic group, respectively.

Univariate and multivariate analyses were used to investigate possible relationships between patient survival data and HER-2 expression, and the subcellular distribution of p21^*WAF*1/*CIP*1^(Table [2](#T2){ref-type="table"}). Univariate analysis showed that HER-2 was significantly associated with a decreased OS (*P*= 0.05) and a decreased RFS (*P*= 0.02) (Table [2](#T2){ref-type="table"} and Fig. [3](#F3){ref-type="fig"}). Cytoplasmic p21^*WAF*1/*CIP*^was associated with a decreased OS and a decreased RFS on univariate analysis (*P*= 0.03) (Table [2](#T2){ref-type="table"}). The multivariate analysis was adjusted for the NPI and treatment groups (no treatment, tamoxifen, other) (Table [2](#T2){ref-type="table"}). Multivariate analysis demonstrated the independent prognostic significance of cytoplasmic p21^*WAF*1/*CIP*^and HER-2 in relation to OS and RFS, while nuclear p21^*WAF*1/*CIP*^was not a prognosticator in this study.

Discussion
==========

HER-2 enhances cancer cell growth, and a number of *in vitro*studies have highlighted mechanisms to explain its oncogenic potential \[[@B18],[@B19],[@B21],[@B29]-[@B31]\]. The relevance of these mechanisms *in vivo*requires further investigation. Analysis of HER-2 expression in breast cancer is important in the interpretation of patient prognosis and treatment response. In this study, the immunohistochemical detection of HER-2 was in keeping with the reported frequency of protein expression in breast cancers. Despite controversy surrounding the relative value of immunohistochemistry and fluorescence *in situ*hybridisation to evaluate HER-2 overexpression, a recent study has shown good concordance for both tests \[[@B32]\].

HER-2 positivity independently predicted prognosis in this group of breast cancers, and was associated with lack of ER expression (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, and Fig. [3](#F3){ref-type="fig"}). Mechanisms underpinning the association of HER-2 with ER-negative tumours need to be determined, with *in vitro*evidence indicating a negative regulation of *HER2*transcription by steroid hormones \[[@B29]\]. Clinical relevance of these pathways may underlie hormone resistance in HER-2-expressing breast cancers \[[@B30]\].

HER-2 potentiates ligand-induced intracellular signalling by targeting the Akt oncoprotein that mediates cytoplasmic PI-3K signalling \[[@B21]\]. Through this mechanism, HER-2 and Akt have been shown to block apoptosis *in vitro*by regulating p21^*WAF*1/*CIP*1^and by enhancing p53 degradation \[[@B21],[@B31]\]. HER-2 increases p21^*WAF*1/*CIP*1^expression to inhibit the mitotic CDC2 kinase and to block Taxol-induced apoptosis \[[@B19]\]. Through an alternative anti-apoptotic pathway, HER-2 induces cytoplasmic p21^*WAF*1/*CIP*^\[[@B21]\]. Immunofluorescence and subcellular fractionation have previously demonstrated cytoplasmic p21^*WAF*1/*CIP*1^in cell lines characterised by transformation, anchorage independence and anti-apoptosis \[[@B13]-[@B16]\].

Predominant cytoplasmic p21^*WAF*1/*CIP*1^has been detected immunohistochemically in breast tumours and in ovarian tumours \[[@B15],[@B17]\]. Previous studies of breast carcinoma have reported the exclusive nuclear localisation of p21^*WAF*1/*CIP*1^\[[@B33]-[@B35]\]. In our study, cytoplasmic p21^*WAF*1/*CIP*1^staining was evident as previously reported \[[@B33],[@B36],[@B37]\] and was based on the method of microwave antigen retrieval (Fig. [1b](#F1){ref-type="fig"}) using an alkaline buffer (Tris-buffered saline/EDTA, pH 9.0), rather than the acidic citrate buffer (pH 6.0) \[[@B17],[@B34],[@B35]\]. This series of breast cancers shows an important association between HER-2 and increased cytoplasmic p21^*WAF*1/*CIP*1^to substantiate *in vitro*findings (Figs [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}) \[[@B21]\]. An inverse association between the HER-2 breast tumours and nuclear p21^*WAF*1/*CIP*1^further implies the ability of HER-2 to mislocalise p21^*WAF*1/*CIP*1^. Nuclear p21^*WAF*1/*CIP*1^is required to preferentially inhibit cyclin/CDK complexes to ensure DNA repair and growth suppression of transformed cells. This process is determined by a carboxyterminal nuclear localisation signal, while mechanisms underlying nuclear export of p21^*WAF*1/*CIP*1^remain to be determined. *In vitro*, active phosphorylated Akt binds p21^*WAF*1/*CIP*1^and phosphorylates threonine 145 in the nuclear localisation signal to produce cytoplasmic p21^*WAF*1/*CIP*1^\[[@B21]\]. In a preliminary series of five breast cancers, immunohistochemical detection of phosphorylated Akt was associated with p21^*WAF*1/*CIP*1^in both the nucleus and the cytoplasm, suggesting an association with HER-2 activation \[[@B21]\]. This implies that the relationship between HER-2 and the subcellular localisation of p21^*WAF*1/*CIP*1^is not exclusive *in vitro*and *in vivo*, but reflects a preferential cytoplasmic localisation of p21^*WAF*1/*CIP*1^.

Further *in vivo*studies are required to establish the significance of phosphorylated Akt in relation to HER-2 and subcellular localisation of p21^*WAF*1/*CIP*1^, with future possibilities that immunodetection of phosphorylated p21^*WAF*1/*CIP*1^may imply activation of this pathway. Clinical relevance of HER-2-expressing tumours with cytoplasmic p21^*WAF*1/*CIP*1^is emphasised by the independent prognostic significance of both parameters. Prognostic significance of cytoplasmic p21^*WAF*1/*CIP*1^at 5 years retains its predictive potential for OS and RFS at 9 years. The combined evaluation of cytoplasmic p21^*WAF*1/*CIP*1^and HER-2 positively did not increase prognostic significance in this study, due to limited patient numbers in the respective subsets. As previously reported, nuclear p21^*WAF*1/*CIP*1^expression was generally low and provided no prognostic information \[[@B17],[@B33],[@B35]\]. Future studies will be required to address what are the best markers.

The biological implications of cytoplasmic p21^*WAF*1/*CIP*1^with respect to the ability to assemble and inhibit cyclin/CDK complexes and to bind apoptosis signal-regulating kinase 1 require further investigation. Studies in cell culture suggest a loss of p53 and growth suppressor function, with inhibition of apoptosis. Subcellular localisation of p21^*WAF*1/*CIP*1^may have relevance underlying mechanisms of HER-2 drug resistance, with the potential for cytoplasmic p21^*WAF*1/*CIP*1^-expressing breast tumours to have increased chemoresistance or hormone resistance. Small patient numbers precluded a separate analysis of treatment relapses in cytoplasmic p21^*WAF*1/*CIP*1^-expressing tumours. The potential to define and modify this pathway through Herceptin inhibition of HER-2 or through Iressa inhibition of HER-1 could influence downstream targets of the pathways such as Akt and p21^*WAF*1/*CIP*1^\[[@B38]\]. The ability of HER-2 to dysregulate p21^*WAF*1/*CIP*1^, a key target of p53, is highly relevant in the context of p53 wild-type cancers, in which growth suppression and apoptosis may be inhibited through mislocalisation of p21^*WAF*1/*CIP*1^.

Conclusion
==========

These presented findings indicate that HER-2 expression may influence tumour outcome through a mechanism regulating the subcellular localisation of p21^*WAF*1/*CIP*1^to produce a cytoplasmic distribution resulting in a loss of its tumour suppressor functions. Cytoplasmic p21^*WAF*1/*CIP*1^predicts poor prognostic tumours and may have a role in HER-2-mediated drug resistance, with the potential for future therapeutic manipulation by Herceptin. Cytoplasmic p21^*WAF*1/*CIP*1^may conceivably be a surrogate marker for HER-2 signalling *in vivo*to classify clinical subgroups of patients most likely to benefit from Herceptin, such that Herceptin inhibition of the pathway could relocate p21^*WAF*1/*CIP*1^to the nucleus. A cytoplasmic to nuclear relocalisation of p21^*WAF*1/*CIP*1^could be a useful biological endpoint to analyse the potential efficacy of Herceptin. Other growth factor pathways involving insulin have recently been implicated in Herceptin resistance, suggesting biological modifications of the Herceptin response \[[@B20],[@B39]\]. Increasingly, there is a rationale for identifying biological markers of drug responsiveness.
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Figures and Tables
==================

![Examples of HER-2 and p21^*WAF*1/*CIP*1^immunoreactivity in infiltrating ductal carcinoma of the breast. Immunostaining was performed as described in Materials and methods, and nuclei were counterstained with haematoxylin. **(a)**A tumour showing HER-2 overexpression, with **(b)**a concomitant predominance of cytoplasmic p21^*WAF*1/*CIP*1^staining and minimal or no nuclear p21^*WAF*1/*CIP*1^expression. **(c)**A HER-2-negative tumour, with **(d)**a predominance of nuclear p21^*WAF*1/*CIP*1^expression compared with cytoplasmic p21^*WAF*1/*CIP*1^, which was proportionately less on intensity distribution scoring in 10 fields. Insets in panels (b) and (d) show higher-power views of the same fields. Magnification × 3--4.](bcr654-1){#F1}

![Relationship between HER-2 and p21^*WAF*1/*CIP*1^localisation. Scatter plots according to HER-2 status and the subcellular localisation of p21^*WAF*1/*CIP*1^measured as an intensity distribution score (IDS). HER-2 staining was analysed as described in Materials and methods. **(a)**Distribution of nuclear p21^*WAF*1/*CIP*1^IDS and medians according to HER-2-negative and HER-2-positive breast cancers, with patient numbers shown. **(b)**Cytoplasmic p21^*WAF*1/*CIP*1^IDS and medians according to HER-2 status, and numbers of patients. Of the 67 patients, nuclear p21^*WAF*1/*CIP*1^was not evaluable in four patients, or in the cytoplasm in six cases. *P*values indicate significance.](bcr654-2){#F2}

![Relationship between HER-2 and prognosis in 67 patients using the log-rank test. **(a)**Overall survival curves according to HER-2 status, classified as negative or positive according to Materials and methods. **(b)**Relapse-free survival curves according to HER-2 expression. Significant *P*values are indicated in bold.](bcr654-3){#F3}

###### 

Clinicopathological variables according to c-erbB2 status

                                HER-2-negative   HER-2-positive   *P*      Overall
  ----------------------------- ---------------- ---------------- -------- --------------
  Total                         54               13                        67
  Oestrogen receptor status                                                
   ≤ 10 fmol/mg                 25               10               0.05\*   35
   \> 10 fmol/mg                29               3                         32
  Node status                                                              
   Negative                     36               8                0.73     44
   Positive                     18               5                         23
  Histologic grade                                                         
   Grade I                      4                0                0.48     4
   Grade II                     17               5                         22
   Grade III                    22               7                         29
   \'Other\'                    11               1                         12
  Nottingham Prognostic Index                                              
   GPG score ≤ 3.4              4                1                0.61     6
   MPG score 3.4--5.4           28               8                         40
   PPG score \> 5.4             7                3                         10
  Age                                                                      
   \< 50 years                  19               8                         28
   ≥ 50 years                   35               5                         39
   Median (range)               56 (32--80)      46 (37--67)      0.03\*   55 (32--80)
  Tumour size                                                              
   ≤ 2 cm                       15               4                         19
   \> 2 cm                      39               9                         48
   Median (range)               2.5 (1--5.5)     2.6 (1--5.3)     0.76     2.5 (1--5.5)

GPG, good prognostic group; MPG, moderate prognostic group; PPG, poor prognostic group. \*Relationship reached significance (*P*≤ 0.05).

###### 

Relationships between HER-2 and p21^*WAF*1/*CIP*1^**localisation and overall survival/relapse-free survival**

                                    Univariate analysis   Multivariate analysis                                   
  ---------------------------- ---- --------------------- ----------------------- -------- -------- ------------- ---------
  Overall survival                                                                                                
   p21                                                                                                            
   p21 nucleus                 64   0.96                  0.77, 1.19              0.70     0.96     0.75, 1.22    0.73
   p21 cytoplasm               63   1.12\*                1.01, 1.25              0.03\*   1.15\*   1.03, 1.28    0.01\*
   HER-2 (2+/3+ versus 0/1+)   63   2.26\*                1.00, 5.27              0.05\*   3.14\*   1.15, 8.64    0.03\*
  Relapse-free survival                                                                                           
   p21                                                                                                            
   p21 nucleus                 64   1.01                  0.84, 1.22              0.89     1.03     0.84, 1.25    0.80
   p21 cytoplasm               63   1.12\*                1.01, 1.24              0.03\*   1.15\*   1.02, 1.28    0.02\*
   HER-2 (2+/3+ versus 0/1+)   63   2.60\*                1.19, 5.71              0.02\*   4.08\*   1.60, 10.39   0.003\*

Hazard ratios, confidence intervals and *P*values are given for the results of both the univariate analyses and the multivariate analyses. For univariate and multivariate analyses, the hazard ratio is given for nuclear and cytoplasmic p21 ^*WAF*1/*CIP*1^per 10 unit increase in intensity distribution score (IDS), along with the 95% confidence interval. The hazard ratio and confidence interval for HER-2 relates to 2+/3+ versus 0/1+. Patients with ductal, lobular or \'mixed\' cancer were included where the marker data was available. The multivariate analysis is adjusted for the Nottingham Prognostic Index (NPI) (nodes, grade and size) and for treatment (tamoxifen/chemotherapy/no treatment), with the NPI based on imputed grades and tumour sizes where the relevant data were missing as described in the statistical methods. \*Relationship reached significance (*P*\< 0.05).
